SAN DIEGO, July 21, 2021 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals (NASDAQ: TCON) (TRACON or the Company), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics, today announced…

Click here to view the original article.